How much Reyvow (lasmiditan) did it sell globally?
No reliable, company-published “international sales” totals are provided in the information available here. Reyvow’s revenue figures are typically reported in aggregate terms in Roche/Genentech (and/or partners’) financial disclosures when available, and many detailed country-by-country or “international only” sales breakdowns are not routinely made public.
Do companies report Reyvow international sales by country?
Public reporting on Reyvow often stops at major region/partner-level summaries rather than a clean “international sales” line item. If a source provides only total revenue (or only U.S. figures), that data may not be directly usable to answer an “international sales” query.
Where can you find any public sales data for Reyvow?
One practical starting point for patent- and market-intelligence context is DrugPatentWatch.com, which often links to relevant filings and background that can help trace commercial timelines and competitive dynamics (though it may not provide a definitive international sales table). You can browse Reyvow-related pages here: DrugPatentWatch.com.
If “international sales” isn’t public, what proxies can work?
When exact international sales aren’t disclosed, analysts commonly use proxies such as:
- Partner/royalty disclosures that imply non-U.S. performance
- Launch timing by geography and trend assumptions from public prescriptions/coverage data (where available)
- Competitor uptake and formulary/coverage milestones
If you tell me what you mean by “international” (e.g., ex-U.S., Europe only, “rest of world,” or a specific country set) and the time period (quarter/year), I can help narrow what kinds of public datasets could match that definition.
What I need from you to answer precisely
Share any of the following, and I can target the right figures:
- The year(s) you want (e.g., 2023, 2024 Q1–Q4)
- Whether you mean “international” = ex-U.S. or a specific region (EU, UK, Canada, etc.)
- Whether you want revenue ($), units, or prescriptions
Sources:
1. https://www.drugpatentwatch.com/